Innovent Biologics Inc., of Hong Kong, completed a $150 million series E round of financing. The round was led by Capital Group Private Markets with its $90 million investment. New investors, including Cormorant Asset Management, Rock Springs Capital and Ally Bridge Group, and existing investors such as Temasek, Hillhouse, Legend Capital, Lilly Asia Venture and Taikang Insurance, also participated in the funding. Read More
PERTH, Australia – Following its IPO on Australia's Securities Exchange in November, Aussie radiopharma company Telix Pharmaceuticals Ltd. has been building up global partnerships to prepare for a commercial build-up of its "theranostic" radiopharmaceuticals. Read More
HONG KONG – An artificial compound derived from vitamin A, acyclic retinoid (ACR), has been shown to selectively target cancer stem cells (CSCs) and reduce the post-therapeutic recurrence of hepatocellular carcinoma (HCC) in a new study and is currently in phase III trials for that indication in Asia. Read More
HONG KONG – Sino-American biopharma company CBT Pharmaceuticals Inc. is set to work with South Korea's Crystalgenomics Inc. on an investigational combination therapy for solid tumors. The two agreed to co-develop and commercialize the final product worldwide. Read More
HONG KONG – Fiscal year 2017 was good for most Chinese pharmaceutical companies, with mainland-listed pharma shares gaining 11 percent in value. Read More
SUZHOU, China – It is no secret that the fortunes of China's biotech sector have never looked brighter. There is a list of reasons – recent regulatory reforms, unwavering government financial support, vast amounts of venture capital, legions of young doctorates and a huge untapped market. But without cross-border partnering, China's biotech industry would look dramatically different. Read More
DUBLIN – Shares in Adocia SA gained 27 percent Thursday on news of a diabetes deal in China with Tonghua Dongbao Pharmaceutical Co. Ltd., under which it will pocket $50 million up front with up to $85 million more to come in potential development milestones, as well as double-digit sales royalties. The agreement covers Biochaperone Combo, its fixed-ratio combination of basal insulin (insulin glargine) and prandial insulin (insulin lispro), as well as its fast-acting insulin formulation Biochaperone Lispro, in China and several other countries. Read More
